Ute Hoch; Jennifer Lynch; Yuji Sato; Shigeki Kashimoto; Fumie Kajikawa; Yasuji Furutani; Jeffrey A. Silverman (2009). Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models. , 64(1), 53–65.
doi:10.1007/s00280-008-0850-3
url to share this paper:
An interview with Sci-Hub Founder Alexandra Elbakyan Who exactly should pay for academic research